Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Engelhardt

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Future Microbiology|January 11, 2020
Ceftobiprole versus daptomycin in <i>Staphylococcus aureus</i> bacteremia: a novel protocol for a double-blind, Phase III trialKamal Hamed, Marc Engelhardt, Mark E Jones, et al.
Plos One|June 24, 2025
Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidanceAndrew F Shorr, Mark E Jones, Silke Friedmann, et al.
Antimicrobial Agents and Chemotherapy|March 15, 2017
Impact of Mucositis on Absorption and Systemic Drug Exposure of IsavuconazoleLaura L Kovanda, Francisco M Marty, Johan Maertens, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|July 20, 2017
Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4Andreas H Groll, Robert Townsend, Amit Desai, et al.
European Journal of Echocardiography : the Journal of the Working Group on Echocardiography of the European Society of Cardiology|October 3, 2006
Analysis of myocardial perfusion or myocardial function for detection of regional myocardial abnormalities. An echocardiographic multicenter comparison study using myocardial contrast echocardiography and 2D echocardiographyRainer Hoffmann, Adrian C Borges, Jaroslaw D Kasprzak, et al.
The Journal of Antimicrobial Chemotherapy|March 28, 2025
Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trialsThomas L Holland, Andrew F Shorr, J Scott Overcash, et al.
Antimicrobial Agents and Chemotherapy|April 20, 2026
Plasma and intrapulmonary pharmacokinetics of ceftibuten and ledaborbactam in healthy male and female adultsKeith A Rodvold, Mark H Gotfried, Carlos Fernando de Oliveira, et al.
American Journal of Cancer Research|June 9, 2023
The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma modelsFilippo Spriano, Luca Aresu, Luciano Cascione, et al.
The Journal of Antimicrobial Chemotherapy|December 2, 2017
Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trialDimitrios P Kontoyiannis, Dominik Selleslag, Kathleen Mullane, et al.
Investigational New Drugs|February 15, 2023
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a studyMarkus Joerger, Thomas Hundsberger, Simon Haefliger, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Future Microbiology|January 11, 2020
Ceftobiprole versus daptomycin in <i>Staphylococcus aureus</i> bacteremia: a novel protocol for a double-blind, Phase III trialKamal Hamed, Marc Engelhardt, Mark E Jones, et al.
Plos One|June 24, 2025
Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidanceAndrew F Shorr, Mark E Jones, Silke Friedmann, et al.
Antimicrobial Agents and Chemotherapy|March 15, 2017
Impact of Mucositis on Absorption and Systemic Drug Exposure of IsavuconazoleLaura L Kovanda, Francisco M Marty, Johan Maertens, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|July 20, 2017
Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4Andreas H Groll, Robert Townsend, Amit Desai, et al.
European Journal of Echocardiography : the Journal of the Working Group on Echocardiography of the European Society of Cardiology|October 3, 2006
Analysis of myocardial perfusion or myocardial function for detection of regional myocardial abnormalities. An echocardiographic multicenter comparison study using myocardial contrast echocardiography and 2D echocardiographyRainer Hoffmann, Adrian C Borges, Jaroslaw D Kasprzak, et al.
The Journal of Antimicrobial Chemotherapy|March 28, 2025
Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trialsThomas L Holland, Andrew F Shorr, J Scott Overcash, et al.
Antimicrobial Agents and Chemotherapy|April 20, 2026
Plasma and intrapulmonary pharmacokinetics of ceftibuten and ledaborbactam in healthy male and female adultsKeith A Rodvold, Mark H Gotfried, Carlos Fernando de Oliveira, et al.
American Journal of Cancer Research|June 9, 2023
The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma modelsFilippo Spriano, Luca Aresu, Luciano Cascione, et al.
The Journal of Antimicrobial Chemotherapy|December 2, 2017
Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trialDimitrios P Kontoyiannis, Dominik Selleslag, Kathleen Mullane, et al.
Investigational New Drugs|February 15, 2023
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a studyMarkus Joerger, Thomas Hundsberger, Simon Haefliger, et al.
Pageof 5